NEWS

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has named Carl O’Connell as president and chief executive officer effective immediately. O’Connell replaces Brian Hutchison, who is stepping down. Hutchison joined the company as executive chairman and interim CEO in June 2018 before being asked…

"Despite an up-and-down year, Catalyst Orthoscience appears poised for takeoff in the new year. One big aid? It has a product surgeons and patients alike love." View Article, Dec 20, 2021

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Catalyst OrthoScience has received clearance from the U.S. Food & Drug Administration to market its reverse shoulder system. Catalyst expects to begin a limited user release in the United States in the second quarter of 2021 followed by a commercial launch later in 2021.

Published peer reviewed study show significant improvements in motion and patient-reported measures in adult shoulder replacement patients of all ages.